The French journal of urology · 2026
Primary management and survival of non-metastatic prostate cancer in subjects aged 75years old and over. Analysis of data from a French cancer registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Trouche-Sabatier Stéphanie G, Trétarre Brigitte, Murez Thibaut, Abdo Nicolas, Poinas Grégoire, Foucan Anne-Sophie, Iborra François
Аннотация
BACKGROUND: In older men, non-metastatic prostate cancer (NMPC) may be under or overtreated, and curative treatments are rarely achieved.
OBJECTIVES: The aim of this study was to analyze the primo-management and survival of non-metastatic prostate cancers in subjects aged 75 and over in a French department.
METHODS: We used retrospective, population-based data to identify subjects aged 75 and over at diagnosis with NMPC between 1 January 2017 and 31 December 2020. Patients were divided into 2 groups: group 1, patients aged 75 to 79years, and group 2, patients aged 80years and over.
RESULTS: We included 1077 patients, 606 in group 1 and 471 in group 2. Of the 794 patients diagnosed on prostate biopsies, 73.7% in group 1 and 35.1% in group 2 received a local curative treatment (P<0.001). Of the 219 NMPC patients diagnosed for a benign prostate hypertrophy (BPH), 73% in group 1 and 69.5% in group 2 were placed on WW after diagnosis and 13.5% in group 1 and 3.7% in group 2 had an active surveillance. Men in group 2 were more frequently put on androgen deprivation therapy (21.3% vs. 5.4%).
CONCLUSIONS: Patients aged 80 and over received fewer local curative treatments, and hormone therapy was overused. In our study, patients with a local curative treatment strategy had a better survival in both age groups. Treatment decisions for these patients should not be based on chronological age, but on cancer prognosis and life expectancy.
OBJECTIVES: The aim of this study was to analyze the primo-management and survival of non-metastatic prostate cancers in subjects aged 75 and over in a French department.
METHODS: We used retrospective, population-based data to identify subjects aged 75 and over at diagnosis with NMPC between 1 January 2017 and 31 December 2020. Patients were divided into 2 groups: group 1, patients aged 75 to 79years, and group 2, patients aged 80years and over.
RESULTS: We included 1077 patients, 606 in group 1 and 471 in group 2. Of the 794 patients diagnosed on prostate biopsies, 73.7% in group 1 and 35.1% in group 2 received a local curative treatment (P<0.001). Of the 219 NMPC patients diagnosed for a benign prostate hypertrophy (BPH), 73% in group 1 and 69.5% in group 2 were placed on WW after diagnosis and 13.5% in group 1 and 3.7% in group 2 had an active surveillance. Men in group 2 were more frequently put on androgen deprivation therapy (21.3% vs. 5.4%).
CONCLUSIONS: Patients aged 80 and over received fewer local curative treatments, and hormone therapy was overused. In our study, patients with a local curative treatment strategy had a better survival in both age groups. Treatment decisions for these patients should not be based on chronological age, but on cancer prognosis and life expectancy.